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 Summary   
Introduction: Adrenomedullin (ADM), a peptide with vasodilatory, natriuretic and diuretic properties, is secreted in 
many tissues and shows multidirectional activity. ADM activity may play an important role in the pathophysiology 
of gestational hypertension (GH) and preeclampsia (PE) by involvement in compensation of failed utero-placental 
unit circulation. 
Aim of the study: The aim of the study was to evaluate the association of –1984A>G ADM gene polymorphism 
with the development of GH and PE in maternal-fetal dyads.
Materials and methods: The study group consisted of 46 hypertensive pregnant subjects (further divided into 
two subgroups: 20 pregnant women with GH and 26 women with PE). 43 healthy pregnant women constituted the 
control group. The study and the control groups as well as the newborns were genotyped for –1984A>G ADM gene 
polymorphism using PCR/RLFP procedures.
Results: Minor –1984G allele was found to be higher in both, the GH (15.00%, OR=3.62, p=0.05), and the PE 
groups (9.62, OR=2.18, p=ns) when compared with controls (4.65%). A tendency for higher frequency of minor 
–1984G allele (12.50 vs. 6.98% in controls, OR=1.91, p=ns) was observed in the newborns from the GH group. It 
was also noteworthy that coexistence of both heterozygous genotypes of maternal-fetal dyads (–1984AG mother/–
1984AG fetus) was overrepresented in the GH group (15.00 vs. 6.98%, OR=2.35, p=ns) and in the PE group 
(11.54 vs. 6.98%, OR=1.74, p=ns) when compared to controls.
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Introduction
Adrenomedullin	 (ADM),	 a	 peptide	 with	 vasodilatory,	
natriuretic	 and	 diuretic	 properties,	 is	 secreted	 in	 many	 tissues	
and	 shows	multidirectional	 activity.	Multifunctional	 biological	
activity	 of	 ADM	 in	 circulatory,	 respiratory,	 neuroendocrine	
and	 immunological	 systems	 suggests	 its	 contribution	 in	 many	
pathophysiological	 processes.	 Numerous	 studies	 investigate	
potential	possibilities	of	ADM	and	its	clinical	application.	ADM	
synthesis	 in	 the	 endothelial	 cells	 and	 its	 participation	 in	 the	
vascular	tone	and	arterial	blood	pressure	regulation	by	different	
mechanisms	deserve	particular	attention	[1,	2].	The	main	ADM	
effects	are	inhibition	of	proliferation	of	vascular	smooth	muscle	
cells	and	stimulation	of	NO	synthesis	[3].	Decreased	sensitivity	
of	blood	vessels	to	vasoconstrictor	factors	leads	to	reduction	of	
blood	 pressure	 value	 [2,	 4].	 It	 seems	 that	ADM	 concentration	
changes	play	an	important	role	in	these	processes.	
ADM	 level	 increases	 in	 the	 course	 of	 physiological	
pregnancy,	 what	 is	 an	 evidence	 of	 an	 active	 role	 of	ADM	 in	
the	process	of	adaptation	of	maternal	circulatory	system	during	
pregnancy	 [5,	 6].	Moreover,	ADM	 concentration	 is	modulated	
by	single	nucleotide	polymorphisms	[7].	Nowadays,	ADM	gene	
expression	 and	 its	 polymorphic	 variants	 are	 being	 investigated	
as	probable	 risk	 factors	of	cardiovascular	diseases	and,	 in	case	
of	 pregnant	 women,	 as	 the	 component	 of	 preeclampsia	 and	
gestational	 hypertension	 development	 [8,	 9,	 10].	 In	 numerous	
researches	ADM	concentration	was	significantly	increased	in	the	
serum	of	 	preeclamptic	women,	 such	as	 the	amniotic	fluid	and	
the	umbilical	blood	[6,	11,	12].	Only	few	investigations	indicated	
a	 decreased	 or	 the	 same	ADM	 concentration	 in	 preeclamptic	
women	 in	 comparison	 to	 healthy	 pregnant	 patients	 [12,	 13].	
Despite	 such	 divergent	 results,	 ADM	 is	 thought	 to	 play	 an	
important	role	in	the	pathophysiology	of	gestational	hypertension	
and	preeclampsia	by	 its	 involvement	 in	compensation	of	 failed	
utero-placental	unit	circulation	[9,	14].	
The	 ADM	 encoding	 gene	 is	 located	 on	 chromosome	
11.	 Recently,	 much	 attention	 has	 been	 paid	 to	 ADM	 gene	
polymorphisms,	which	may	modulate	ADM	activity	and	might	be	
involved	in	the	etiology	of	different	diseases.	One	of	the	studied	
polymorphisms	 is	 -1984A>G	 variant	 in	 the	 promoter	 region	
of	 the	 ADM	 gene,	 which	 probably	 enhances	 adrenomedullin	
transcription	and,	in	consequence,	increases	ADM	concentration	
[15].
In	 numerous	 investigations	 of	 perinatal	 diseases,	 only	 the	
maternal	genotype	effects	have	been	evaluated.	At	present,	it	is	
postulated	that	even	fetal	genotype	could	influence	the	perinatal	
outcome,	 either	 on	 its	 own	 or	 by	 interacting	 with	 maternal	
genes.	 Since	 preeclampsia	 could	 result	 from	 maternal-fetal	
incompatibility,	the	influence	of	genetic	variants	in	maternal-fetal	
dyads	should	also	be	taken	into	consideration.	In	this	area	several	
polymorphisms	in	different	genes	have	been	investigated.	
Conclusions: The observed tendency for overrepresentation of minor -1984G ADM allele in the GH and PE 
women and their newborns, despite lack of statistical significance, suggests participation of this genetic variant in 
the pathogenesis of the mentioned conditions. Additionally, the obtained results could indicate that maternal-fetal 
gene-gene interaction may be a potential source of adverse perinatal outcomes.
 Key words: preeclampsia / gestational hypertension / adrenomedullin / 
        / genetic polymorphism / 
 Streszczenie   
Wstęp: Adrenomedullina (ADM), białko o właściwościach wazodylatacyjnych, natriuretycznych i diuretycznych, 
wydzielana jest przez wiele tkanek i wykazuje wielokierunkowe działanie. ADM może odgrywać ważną rolę 
w patofizjologii nadciśnienia ciążowego (GH - gestational hypertension) oraz stanu przedrzucawkowego (PE - 
preeclampsia) poprzez wpływ na zaburzoną kompensację w krążeniu maciczno-łożyskowym. 
Cel badań: ocena związku polimorfizmu –1984A>G genu ADM z rozwojem GH oraz PE w parach matka-płód. 
Materiał i metody: Grupa badana 46 kobiet ciężarnych z nadciśnieniem podzielona została na dwie podgrupy: 20 
ciężarnych z GH oraz 26 ciężarnych z PE. Grupę kontrolną stanowiły 43 zdrowe kobiety ciężarne. Oznaczanie 
częstości genotypów polimorfizmu –1984A>G genu ADM u wszystkich kobiet i ich noworodków przeprowadzono 
z zastosowaniem metody PCR/RLFP.
Wyniki: Obserwowano tendencję do częstszego występowania zmutowanego allela –1984G w obydwu grupach GH 
(15,00%, OR=3,62, p=0,05), oraz w grupie PE (9,62%, OR=2,18, p=ns) w porównaniu do grupy kontrolnej (4,65%). 
U noworodków z grupy GH odnotowano tendencję do częstszego występowania zmutowanego allela –1984G 
(12,50 vs. 6,98%, OR=1,91, p=ns). Warto również zauważyć, że współwystępowanie obydwu heterozygotycznych 
genotypów w parach matka-dziecko (–1984AG matka/–1984AG płód) było znacznie wyższe w grupie GH (15,00 
vs. 6,98%, OR=2,35, p=ns), jak również w grupie PE (11,54 vs. 6,98%, OR=1,74, p=ns) w porównaniu do grupy 
kontrolnej. 
Wnioski: Tendencja do częstszego występowania zmutowanego allela -1984G ADM u kobiet z GH oraz PE i ich 
noworodków, mimo braku istotności statystycznej, sugeruje udział tego wariantu genetycznego w patogenezie 
powyższych powikłań. Dodatkowo, otrzymane rezultaty wskazują, że matczyno-płodowe interakcje gen-gen mogą 
być potencjalnie przyczyną wystąpienia powikłań w przebiegu ciąży.
 Słowa kluczowe: stan przedrzucawkowy / nadciśnienie ciążowe / adrenomedullina /
                  / polimorfizm genetyczny / 
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Aim
The	 aim	 of	 this	 study	 was	 to	 evaluate	 the	 association	 of	
–1984A>G ADM	gene	polymorphism	with	the	development	of	
GH	and	PE	in	maternal-fetal	dyads.
Material and methods
Patients: The	research	involved	two	groups	of	women:	46	
hypertensive	pregnant	patients	(mean	age	30.4±4.2	years,	mean	
systolic	blood	pressure	156.4±20.3	mmHg,	mean	gestational	age	
at	delivery	35.7±4.0	week	of	pregnancy)	and	43	healthy	pregnant	
controls	(mean	age	29.7±5.8	years,	mean	systolic	blood	pressure	
112.2±11.3	 mmHg,	 mean	 gestational	 age	 at	 delivery	 39.0±1.3	
week	 of	 pregnancy)	 (Table	 I).	The	 patients	were	 enrolled	 into	
the	 study	 at	 the	 Perinatology	 and	Women’s	Diseases	Division,	
Poznan	University	of	Medical	Sciences,	between	January	2008	
and	May	2009.	All	women	gave	their	informed	written	consent	
to	participate	in	research.	The	Bioethical	Committee	of	Poznan	
University	of	Medical	Sciences	approved	the	study	(03/08).	All	
patients	were	Caucasian,	 of	 Polish	 nationality,	 residents	 of	 the	
Wielkopolska	region.	In	each	case	gestational	age	was	calculated	
using	 the	 date	 of	 the	 last	 menstruation	 and	 confirmed	 by	 an	
ultrasound	investigation.
The	 study	 group	 of	 hypertensive	 pregnant	 women	 (n=46,	
singleton	 pregnancy)	 was	 further	 divided	 into	 two	 subgroups:	
patients	with	gestational	hypertension	(n=20,	GH	group;	mean	age	
30.3±2.8	years,	mean	systolic	blood	pressure	148.8±7.1	mmHg,	
mean	gestational	age	at	delivery	38.6±2.1	week	of	pregnancy)	and	
patients	with	preeclampsia	(n=26,	PE	group;	mean	age	30.5±4.9	
years,	 mean	 systolic	 blood	 pressure	 162.3±21.2	 mmHg,	 mean	
gestational	age	at	delivery	34.0±8.5	week	of	pregnancy)	(Table	
I).	Gestational	hypertension	and	preeclampsia	were	 recognized	
according	 to	 the	 ACOG	 (American College of Obstetricians 
and Gynecologists)	 criteria	 (blood	 pressure	 ≥	 140/90	 mmHg,	
and,	 in	 PE	 cases,	 the	 presence	 of	 proteinuria	 ≥	 300	mg/24	 h).	
Women	with	multifetal	pregnancies,	preterm	rupture	of	amniotic	
membranes,	 intraamniotic	 infection,	 diabetes	 mellitus,	 chronic	
hypertension,	other	cardio-vascular	and	renal	diseases,	as	well	as	
cigarette	smokers	were	excluded	from	the	study.
The	control	group	consisted	of	43	healthy	pregnant	women.	
The	 inclusion	 criteria	 to	 the	 control	 group	 were:	 singleton	
pregnancy,	blood	pressure	<	140/90	mmHg,	lack	of	proteinuria,	
absence	 of	 internal	 diseases	 and	 uncomplicated	 course	 of	
pregnancy.
Genetic analysis:	 In	 both	 groups	 of	 patients	 and	 their	
newborns	 (umbilical	 blood)	 the	 frequency	 of	 genotypes	 and	
alleles	of	–1984A>G	ADM	gene	polymorphism	were	evaluated.	
From	each	woman	3-4	mL	venous	blood	samples	were	collected.	
The	venous	umbilical	blood	samples	were	collected	immediately	
after	 the	delivery	of	 the	placenta.	Both	 samples	were	 stored	at	
-20ºC	until	the	DNA	isolation	was	performed.
Genomic	DNA	was	extracted	from	blood	 leucocytes	using	
the	QIAamp	DNA	Blood	Mini	Kit	 (QIAGEN	 Inc.,	Germany).	
Genotyping	 was	 performed	 using	 polymerase	 chain	 reaction	
(PCR)	 and	 restriction	 length	 fragment	 polymorphism	 (RLFP)	
procedures.	2	starters	were	used	for	amplification:	F-CAA	GTG	
GAA	GCT	GGC	GAC	AAG,	R-CGG	ACC	TGA	ATT	CCA	TCT	
GAG	G	(Tib	MolBiol,	Poland).	PCR	reaction	was	performed	in	
Dyad	DNA	Engine	Thermocycler	(MJ	Research	Inc.,	USA).	The	
initial	denaturation	was	performed	at	95ºC	for	3	min.,	then	through	
30	 cycles	 the	 following	 conditions	 were	 used:	 denaturation	 at	
94ºC	for	30	s,	annealing	at	63ºC	for	30	s,	and	elongation	at	72ºC	
for	60	s.	The	final	elongation	was	performed	at	72oC	for	10	min.	
PCR	products	(377	bp)	were	hydrolyzed	with	restriction	enzyme	
TaaI	 (Tsp4CI)	 (Fermentas,	Lithuania).	Analysis	of	 the	digested	
fragments	was	conducted	with	agarose	gel	by	electrophoresis	(2.5	
%	agarose	gel).	Products	of	the	electrophoresis	were	stained	with	
ethidium	bromide	and	visualized	under	UV	light	for	evaluation,	
using	the	system	of	documentation	(KS	4000i/ImagePC,	Syngen	
Biotech,	USA).	The	AA	genotype	was	identified	by	the	presence	
of	377	bp	long	band,	heterozygous	AG	genotype	by	377	bp,	241	
bp,	and	136	bp	bands	and	homozygous	GG	genotype	by	241	bp	
and	136	bp	bands.
Statistical analysis: Statistical	 analysis	 was	 performed	 by	
SPSS	15.0.	p	value	lower	than	0.05	was	considered	statistically	
significant.	 Frequencies	 of	 genotypes	 were	 compared	 by	 chi-
square	test.	Expected	genotype	frequencies	were	calculated	from	
allele	frequencies	using	the	Hardy-Weinberg	equation.
Table  I .  Description of the mothers from the investigated groups of hypertensive pregnant women and controls. 
GH + PE GH PE Control group
Number of dyads 46 20 26 43
Age 
(years)
mean±SD 30.4±4.2 30.3±2.8 30.5±4.9 29.7±5.8
range 230-400 25.0-38.0 23.0-40.0 17.0-39.0
median 30.0 30.0 30.5 30.5
Gestational age 
at delivery (weeks)
mean±SD 35.7±4.0 38.6±2.1 34.0±8.5 39.0±1.3
range 25.0-42.0 36.0-42.0 25.0-40.0 37.0-42.0
median 36.5 38.5 33.0 39.0
Systolic blood 
pressure (mmHg)
mean±SD 156.4±20.3 148.8±7.1 162.3±21.2 112.2±11.3
range 110.0-200.0 110.0-180.0 120.0-200.0 90.0-135.0
median 160.0 155.0 160.0 110.0
Diastolic blood 
pressure
(mmHg)
mean±SD 98.2±13.5 93.5± 0.0 101.7±0.0 71.4±7.7
range 60.0-130.0 60.0-110.0 70.0-130.0 60.0-85.0
median 100.0 100.0 100.0 70.0
GH – gestational hypertension, PE – preeclampsia
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Results
Analysis of newborn clinical data
Statistically	 significant	 lower	 birth	 weight	 was	 observed	
in	the	group	of	newborns	from	hypertensive	women	2553.1	vs. 
3501.7	 g	 in	 controls	 (p<0.0001).	Lower	Apgar	 score	 values	 at	
first	(7.3	vs.	9.7	in	controls,	p=ns)	and	fifth	minute	(8.7	vs.	10.0	in	
controls,	p=ns),	mean	values	of	arterial	(7.22	vs.	7.23	in	controls,	
p=ns)	and	venous	(7.27	vs.	7.32in	controls,	p=ns)	pH,	and	lower	
placenta	weight	(498.6	vs.	632.3	g	in	controls,	p=ns)	were	also	
observed	in	that	group	(Table	II).
Frequency of genotypes and alleles of –1984A>G ADM gene 
polymorphism in mothers
A	tendency	for	higher	frequency	of	heterozygotic	–1984AG 
and	homozygotic	–1984GG genotypes	 (21.74	vs.	 9.30%	 in	 the	
control	group,	OR=2.71,	p=ns)	and	higher	frequency	of	–1984G 
allele	 (11.96	vs.	4.65%	 in	 the	control	group	OR=2.78,	p=0.07)	
were	observed	in	the	whole	study	group	(n=46)	when	comparing	
to	 controls	 (n=43).	 Similarly,	when	we	 compared	 the	GH	 and	
PE	groups	separately	to	the	control	group,	overrepresentation	of	
heterozygotic	–1984AG	 and	 homozygotic	–1984GG genotypes	
in	 the	GH	patients,	 just	as	heterozygotic	–1984AG	genotype	in	
the	PE	group,	was	also	observed	(respectively,	25.00%	in	the	GH	
group,	OR=3.25,	p=ns	and	19.23%	in	 the	PE	group,	OR=2.32,	
p=ns	vs.	9.30%	in	controls).	A	tendency	for	higher	frequency	of	
–1984G allele	in	both	studied	groups	in	comparison	to	the	control	
group	was	noted	(in	the	GH	group	15.00	vs.	4.65%	in	controls,	
OR=3.62,	 p=0.05,	 and	 in	 the	 PE	 group	 9.62	 vs.	 4.65%	 in	 the	
control	group,	OR=2.18,	p=ns)	(Table	III).
Frequency of genotypes and alleles of –1984A>G ADM gene 
polymorphism in newborns
In	newborns	of	hypertensive	women	slight	higher	frequency	
of	 heterozygotic	 –1984AG genotype	 and	 –1984G allele	 was	
Table  I I I .  Frequency of ADM genotypes and alleles in mothers in the hypertensive pregnant women group and the controls.
ADM Hypertensive pregnantsn=46
GH
n=20
PE
n=26
Control group
n=43
observed 
value
n (%)
expected 
value
n (%)
observed 
value
(%)
expected 
value
(%)
observed 
value
n (%)
expected 
value
(%)
observed 
value
n (%)
expected 
value
(%)
Genotypes
AA 36 (78.26) 77.51 15 (75.00) 72.25 21 (80.77) 81.69 39 (90.70) 90.91
AG 9 (19.56) 21.06 4 (20.00) 25.50 5 (19.23) 17.39 4 (9.30) 8.87
GG 1 (2.18) 1.43 1 (5.00) 2.25 0 (0.00) 0.92 0 (0.00) 0.22
Total 46 (100.00) 100.00 20 (100.00) 100.00 26 (100.00) 100.00 43 (100.00) 100.00
Alleles
A 81 (88.04) - 34 (85.00) - 47 (90.38) - 82 (95.35) -
G 11 (11.96) - 6 (15.00) - 5 (9.62) - 4 (4.65) -
Total 92 (100.00) - 40 (100.00) - 52 (100.00) - 86 (100.00) -
Table  I I .  Description of the newborns from the investigated groups of hypertensive pregnant women and controls.
Hypertensive pregnants Control group p
Number of dyads 46 43
Birth weight (g)
mean±SD 2553,1±1167.2 3501.7±528.4 <0,0001
range 620.0-4580.0 2430.0-4610.0
median 2540.0 3430.0
Ap 1
mean±SD 7.3± 3.1 9.7±0.6 p=ns
range 1.0-10.0 8.0-10.0
median 9.0 10.0
Ap 5
mean±SD 8.7±1.8 10.0±0.0 p=ns
range 3.0-10.0 10.0-10.0
median 10.0 10.0
pH venous
mean±SD 7.27±0.10 7.32±0.08 p=ns
range 7.01-7.45 7.14-7.48
median 7.28 7.34
pH arterial
mean±SD 7.22±0.11 7.23±0.08 p=ns
range 6.95-7.43 7.04-7.41
median 7.23 7.24
Placental
weight (g)
mean±SD 498.6±224.6 632.3±123.9 p=ns
range 160.0-1200.0 420.0-900.0
median 470.0 605.0
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observed	 when	 compared	 to	 controls	 (respectively,	 19.57	 vs. 
13.95%,	OR=1.50,	p=ns	 and	 9.78	vs.	 6.98%,	OR=1.44,	p=ns).	
The	 frequency	 of	 heterozygotic	 –1984AG genotype	 (15.38	 vs. 
13.95%	in	controls	OR=1.12,	p=ns)	and	–1984G allele	(7.69	vs. 
6.98%,	OR=1.11,	p=ns)	was	 similar	 in	 the	 PE	 and	 the	 control	
group.	However,	almost	a	two-fold	higher	frequency	of	–1984AG 
genotype	(25.00%)	in	comparison	to	the	control	group	(13.95%,	
OR=2.06,	p=ns)	was	noted	in	the	newborns	from	the	GH	group.	
The	same	observation	was	connected	with	mutated	–1984G allele.	
The	 frequency	 of	 this	 variant	was	 also	 almost	 two-fold	 higher	
in	the	newborns	from	the	GH	group	when	compared	to	controls	
(12.50	vs.	6.98%,	OR=1.91,	p=ns).	All	the	observed	values	were	
in	accordance	with	Hardy-Weinberg	equilibrium	(Table	IV).
Co-occurrence of genotypes in maternal-fetal dyads
Finally,	 we	 compared	 the	 co-occurrence	 of	 investigated	
genotypes	 in	 mothers	 and	 fetuses	 from	 the	 study	 groups.	
Interestingly,	 an	 overrepresentation	 of	 coexistence	 of	 both	
heterozygous	 genotypes	 in	 maternal-fetal	 dyads	 (–1984AG 
mother/–1984AG fetus)	 was	 observed	 in	 the	 entire	 group	 of	
hypertensive	women	 (GH	+	 PE):	 13.04	 vs.	 6.98%	 in	 controls,	
OR=2.00,	p=ns)	(Table	V).
The	fact	that	the	coexistence	of	both	heterozygous	genotypes	
in	the	maternal-fetal	dyads	(–1984AG mother/–1984AG fetus)	in	
the	GH	group	(15.00	vs.	6.98%,	OR=2.35,	p=ns)	and	in	the	PE	
group	 (11.54	 vs.	 6.98%,	 OR=1.74,	 p=ns)	 was	 overrepresented	
when	compared	to	the	control	group	seems	noteworthy.	(Table	V).
Discussion
Recent	studies	showed	that	physiological	course	of	pregnancy	
depends	on	the	proper	“cooperation”	between	the	mother	and	the	
fetus.	 Disturbances	 of	 balance	 in	 the	 maternal-fetal	 dyads	 are	
one	of	the	mechanisms	involved	in	the	development	of	perinatal	
diseases.	Fetal	genome	has	been	suggested	to	have	an	influence	on	
Table  V.  Co-occurrence of ADM gene polymorphism genotypes in maternal-fetal dyads in the studied groups.
-1984A>G ADM
Mother
Total
AA AG GG
Hypertensive
pregnants (n=46) Newborn
AA 34 (73.91) 3 (6.52) 0 (0.00) 37 (80.43)
AG 2 (4.35) 6 (13.04) 1 (2.17) 9 (19.56)
GG 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Total 36 (78.26) 9 (19.56) 1 (2.17) 46 (100.00)
GH Newborn
AA 14 (70.00) 1 (5.00) 0 (0.00) 15 (75.00)
AG 1 (5.00) 3 (15.00) 1 (5.00) 5 (25.00)
GG 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Total 15 (75.00) 4 (20.00) 1 (5.00) 20 (100.00)
PE Newborn
AA 20 (76.92) 2 (7.69) 0 (0.00) 22 (84.61)
AG 1 (3.85) 3 (11.54) 0 (0.00) 4 (15.39)
GG 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Total 21 (80.77) 5 (19.23) 0 (0.00) 26 (100.00)
Control
group
(n=43)
Newborn
AA 36 (83.72) 1 (2.32) 0 (0.00) 37 (86.04)
AG 3 (6.98) 3 (6.98) 0 (0.00) 6 (13.96)
GG 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Total 39 (90.70) 4 (9.30) 0 (0.00) 43 (100.00)
 
Table  IV.  Frequency of ADM genotypes and alleles in newborns from the hypertensive pregnant women group and the controls.
ADM Hypertensive pregnantsn=46
GH
n=20
PE
n=26
Control group
n=43
observed 
value
n (%)
expected 
value
n (%)
observed 
value
(%)
expected 
value
(%)
observed 
value
n (%)
expected 
value
(%)
observed 
value
n (%)
expected 
value
(%)
Genotypes
AA 37 (80.43) 81.4 15 (75.00) 76.56 22(84.62) 85.21 37 (86.05) 86.53
AG 9 (19.57) 17.65 5 (25.00) 21.88 4(15.38) 14.20 6 (13.95) 12.98
GG 0 (0.00) 0.95 0 (0.00) 1.56 0 (0.00) 0.59 0 (0.00) 0.49
Total 46 (100.00) 100.00 20 (100.00) 100.00 26 (100.00) 100.00 43 (100.00) 100.00
Alleles
A 83 (90.22) - 35 (87.50) - 48(92.31) - 80 (93.02) -
G 9 (9.78) - 5 (12.50) - 4 (7.69) - 6 (6.98) -
Total 92 (100.00) - 40 (100.00) - 52 (100.00) - 86 (100.00) -
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the	pregnancy	course,	among	others	by	interacting	with	maternal	
genes.	 An	 investigation	 of	 adverse	 perinatal	 effects	 should	
consider	both,	maternal	and	fetal	genetic	conditions	and,	indeed,	
in	 some	 current	 studies	 the	 correlation	 between	 hypertensive	
disorders	 in	 pregnant	 women	 and	 gene	 polymorphisms	 at	
maternal-fetal	 interactivity	 has	 been	 reported	 [16,	 17,	 18,	 19].	
Therefore,	 identification	 of	 candidate	 genes	 involved	 in	 PE	
pathogenesis,	and	especially	research	connected	with	imbalance	
in	maternal-fetal	dyads,	may	offer	new	and	important	insight	into	
its	prevention	and	treatment.
There	 are	 only	 few	 studies	 focused	 on	 genetic	 variants	 of	
hypertensive	disorders	including	maternal-fetal	dyads	genotyping.	
A	 study	 analyzing	 a	 correlation	 between	 polymorphisms	 of	
transforming	growth	factor	beta	3	(TGF-beta	3)	gene	and	PE/GH	
risk	was	performed	in	a	group	of	136	subjects	and	169	controls.	
Four	 single	 nucleotide	 polymorphisms	 (SNPs)	 in	 TGF-beta	 3	
gene	 (rs3917200,	 rs114664142,	 rs2268624,	 rs2205181)	 were	
genotyped.	 The	 most	 interesting	 results	 were	 connected	 with	
rs114664142	polymorphism	(occurred	genotypes:	CC, CT, TT).	
The	mothers	with	minor	T	 allele	were	 not	 inclined	 to	 develop	
either	 	GH	or	PE.	On	 the	other	hand,	 fetuses	with	at	 least	one	
copy	 of	 the	minor	 allele	 for	 rs114664142	 polymorphism	were	
delivered	more	frequently	 in	 the	group	of	hypertensive	women	
(23%	vs.	16%	in	controls)	and	the	risk	of	developing	GH/PE	was	
lower	 among	mother-fetus	 dyads	when	 the	 fetus	was	 carrying	
one	or	 two	copies	of	T	allele	 in	comparison	 to	 fetuses	with	no	
T	 allele.	 None	 of	 the	 other	 polymorphisms	 were	 associated	
with	an	increased	risk	of	hypertensive	disorders	in	the	course	of	
pregnancy	[20].
Furthermore,	 an	 interesting	 study	 was	 performed	 by	 Hill	
et	 al.,	 who	 investigated	 the	 association	 between	 catechol-O-
methyltransferase	(COMT)	haplotypes,	methylenetetrahydrofolate	
reductase	(MTHFR)	677C>T	polymorphism	and	PE	risk	(1103	
maternal-fetal	 dyads).	 Four	 SNPs	 of	 COMT	 gene	 (rs6269,	
rs4633,	rs4680,	and	rs4818)	were	shown	to	be	connected	with	the	
enzyme	activity.	The	study	revealed	that	maternal	ACCG	COMT	
haplotype	was	correlated	with	a	 reduced	 risk	of	PE	 (p=0.004).	
Fetal	ATCA	COMT	haplotype	and	the	presence	of	fetal	MTHFR	
minor	677T allele	increased	PE	risk	(p=0.022)	[21].
To	 the	 best	 of	 our	 knowledge,	 this	 is	 the	 first	 research	
concerning	at	the	same	time	maternal	and	fetal	–1984A>G	ADM	
gene	polymorphism	and	its	correlation	to	hypertensive	disorders	
during	 pregnancy.	 Despite	 lack	 of	 statistically	 significant	
differences,	 we	 have	 observed	 high	 overrepresentation	 of	
the	 	 mutated	 –1984G	 allele	 in	 the	 whole	 hypertensive	 group	
(OR=2.78),	as	well	as	 in	the	GH	and	PE	groups.	However,	 the	
analysis	of	maternal-fetal	dyads	frequency	and	their	influence	on	
GH/PE	development	in	pregnant	women	was	the	most	important	
fact.	 Our	 study	 evaluated	 genotypes	 and	 allele	 frequencies	 in	
pregnant	women	with	PE	and	GH,	as	well	as	in	the	umbilical	blood	
of	their	newborns,	demonstrate	a	possible	role	of	both	maternal	
and	 fetal	 genotype	 in	 increasing	 the	 risk	 of	PE.	Moreover,	 the	
overrepresentation	of	coexistence	of	both	heterozygous	genotypes	
in	the	maternal-fetal	dyads	(–1984AG mother/–1984AG fetus)	in	
the	whole	group	of	hypertensive	women	(GH	+	PE)	(OR=2.0),	
the	 GH	 group	 (OR=2.35)	 and	 the	 PE	 group	 (OR=1.74)	 was	
observed.	These	exciting	results	could	suggest	a	participation	of	
minor	G allele	in	the	pathogenesis	of	PE	and	GH	and,	additionally,	
highlight	the	importance	of	maternal-fetal	dyads	analysis.
Unfortunately,	there	are	some	limitations	to	our	research.	First	
of	all,	PE	and	GH	etiology	is	most	probably	multifactorial.	Thus,	
it	 is	 incorrect	 to	 assume	 that	 genetic	 variability	 alone	 is	 a	 risk	
factor	of	hypertensive	disorders	in	pregnancy	[22,	23].	However,	
we	eliminated	known	risk	 factors	of	PE	and	GH.	Women	with	
multifetal	pregnancies,	preterm	rupture	of	amniotic	membranes,	
intraamniotic	infection,	diabetes	mellitus,	chronic	hypertension,	
other	 cardio-vascular	 and	 renal	 diseases,	 as	 well	 as	 cigarette	
smokers,	were	 excluded	 from	 the	 study.	 Secondly,	 a	 relatively	
small	 group	 of	 investigated	 maternal-fetal	 dyads	 might	 have	
adversely	influenced	the	accuracy	of	the	obtained	results.	Finally,	
our	study	was	conducted	on	Caucasian	patients,	of	Polish	origin.	
Genotypes	 and	 allele	 frequencies	 vary	 among	 different	 races	
and	populations.	Thus,	it	is	necessary	to	emphasize	the	fact	that	
further	analysis,	with	involvement	of	more	comprehensive	data,	
is	needed.	Due	to	the	fact	that	studies	concerning	the	involvement	
of	ADM	in	the	etiology	of	GH	and	PE	are	scarce,	the	obtained	
results	 are	 difficult	 to	 interpret.	 There	 is	 a	 need	 to	 continue	
studies	confirming	the	participation	of	ADM	in	the	pathogenesis	
of	 various	 diseases,	 as	well	 as	 research	 confirming	 its	 clinical	
usefulness	and	application.	
Probably	only	a	complex	analysis	of	the	processes	involved	
in	the	modulation	of	ADM	gene	transcription	factors	and	studies	
concerning	polymorphic	variants	of	ADM	gene,	ADM	receptor/	
receptor	gene,	will	allow	us	to	figure	out	the	actual	role	of	this	
peptide	in	the	etiology	of	hypertensive	disorders	during	pregnancy	
[24,	25].
Conclusions
The	 observed	 tendency	 for	 overrepresentation	 of	 minor	
-1984G ADM	allele	in	the	GH	and	PE	women	and	their	newborns,	
despite	lack	of	statistical	significance,	suggests	a	participation	of	
this	genetic	variant	in	the	pathogenesis	of	these	two	conditions.	
Additionally,	 the	 obtained	 results	 could	 indicate	 that	maternal-
fetal	gene-gene	interaction	may	be	a	potential	source	of	adverse	
perinatal	outcome.	To	the	best	of	our	knowledge,	this	is	the	first	
study	 dealing	 with	 maternal	 and	 fetal	 –1984A>G	ADM	 gene	
polymorphism	 and	 its	 correlation	 to	 hypertensive	 disorders	
during	pregnancy,	thus	further	analysis	is	essential.
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